-
Something wrong with this record ?
A comparison of the therapeutic efficacy of diclofenac in osteoarthritis: a systematic review of randomised controlled trials
K. Pavelka,
Language English Country England, Great Britain
Document type Comparative Study, Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't, Review
- MeSH
- Anti-Inflammatory Agents, Non-Steroidal therapeutic use MeSH
- Diclofenac adverse effects therapeutic use MeSH
- Humans MeSH
- Meta-Analysis as Topic MeSH
- Osteoarthritis drug therapy epidemiology MeSH
- Randomized Controlled Trials as Topic statistics & numerical data MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Evaluation Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Comparative Study MeSH
OBJECTIVE: Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) commonly prescribed for pain relief in osteoarthritis (OA). The relative efficacy of diclofenac compared to other pain relief medications used in OA (e.g., alternative NSAIDs, cyclooxygenase type 2 [COX-2] inhibitors) is uncertain. The objective of this systematic review is to compare the current evidence on efficacy of diclofenac versus other pain relief medications. RESEARCH DESIGN AND METHODS: A systematic literature search was carried out for randomised, well controlled clinical trials comparing the efficacy of diclofenac with other pain relief medications in OA (reviews, meta-analyses and n = 1 trials were excluded). The databases searched were EMBASE, Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, and Ovid MEDLINE Daily Update. Articles were included from 1999 onwards. Retrieved articles were discussed by comparator medication. RESULTS: Of the 263 articles identified in the literature search, 37 were eventually included in this review. These were comparisons with the selective COX-2 inhibitors etoricoxib, celecoxib, lumiracoxib and rofecoxib; comparisons with the NSAIDs aceclofenac, dexketoprofen, etodolac, lornoxicam, meloxicam, nabumetone and nimesulide; and comparisons to acetaminophen, tramadol, diacerein, oxaceprol, oral hydrolytic enzyme therapies, Chinese herbal remedies and castor oil supplementation. Overall, in the majority of the trials at therapeutic doses diclofenac provided similar efficacy to comparator treatments; and in general diclofenac was able to support its position as a reference medication of choice for OA trials. CONCLUSIONS: The efficacy of diclofenac is largely unchallenged in that it remains as effective as newer pain relief medications employed in OA. A review of the available data demonstrates that diclofenac continues to provide physicians with a benchmark pharmacological treatment for OA.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12024185
- 003
- CZ-PrNML
- 005
- 20121207093012.0
- 007
- ta
- 008
- 120815s2012 enk f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1185/03007995.2011.649848 $2 doi
- 035 __
- $a (PubMed)22168216
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Pavelka, K $u Institute of Rheumatology and Clinic of Rheumatology, Charles University, Prague, Czech Republic. pavelka@revma.cz
- 245 12
- $a A comparison of the therapeutic efficacy of diclofenac in osteoarthritis: a systematic review of randomised controlled trials / $c K. Pavelka,
- 520 9_
- $a OBJECTIVE: Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) commonly prescribed for pain relief in osteoarthritis (OA). The relative efficacy of diclofenac compared to other pain relief medications used in OA (e.g., alternative NSAIDs, cyclooxygenase type 2 [COX-2] inhibitors) is uncertain. The objective of this systematic review is to compare the current evidence on efficacy of diclofenac versus other pain relief medications. RESEARCH DESIGN AND METHODS: A systematic literature search was carried out for randomised, well controlled clinical trials comparing the efficacy of diclofenac with other pain relief medications in OA (reviews, meta-analyses and n = 1 trials were excluded). The databases searched were EMBASE, Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, and Ovid MEDLINE Daily Update. Articles were included from 1999 onwards. Retrieved articles were discussed by comparator medication. RESULTS: Of the 263 articles identified in the literature search, 37 were eventually included in this review. These were comparisons with the selective COX-2 inhibitors etoricoxib, celecoxib, lumiracoxib and rofecoxib; comparisons with the NSAIDs aceclofenac, dexketoprofen, etodolac, lornoxicam, meloxicam, nabumetone and nimesulide; and comparisons to acetaminophen, tramadol, diacerein, oxaceprol, oral hydrolytic enzyme therapies, Chinese herbal remedies and castor oil supplementation. Overall, in the majority of the trials at therapeutic doses diclofenac provided similar efficacy to comparator treatments; and in general diclofenac was able to support its position as a reference medication of choice for OA trials. CONCLUSIONS: The efficacy of diclofenac is largely unchallenged in that it remains as effective as newer pain relief medications employed in OA. A review of the available data demonstrates that diclofenac continues to provide physicians with a benchmark pharmacological treatment for OA.
- 650 _2
- $a antiflogistika nesteroidní $x terapeutické užití $7 D000894
- 650 _2
- $a diklofenak $x škodlivé účinky $x terapeutické užití $7 D004008
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a metaanalýza jako téma $7 D015201
- 650 _2
- $a osteoartróza $x farmakoterapie $x epidemiologie $7 D010003
- 650 _2
- $a randomizované kontrolované studie jako téma $x statistika a číselné údaje $7 D016032
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a hodnotící studie $7 D023362
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 773 0_
- $w MED00009520 $t Current medical research and opinion $x 1473-4877 $g Roč. 28, č. 1 (2012), s. 163-78
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22168216 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m
- 990 __
- $a 20120815 $b ABA008
- 991 __
- $a 20121207093046 $b ABA008
- 999 __
- $a ok $b bmc $g 946333 $s 781513
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 28 $c 1 $d 163-78 $i 1473-4877 $m Current medical research and opinion $n Curr Med Res Opin $x MED00009520
- LZP __
- $a Pubmed-20120815/12/02